Iodine-125 seed implantation combined with arterial chemoembolization therapy for pain palliation in metastatic bone cancer: a retrospective study. Issue 2 (1st February 2019)

• Record Type: Journal Article
• Authors: Yang, Zeran; Chen, Guang; Cui, Ye; Su, Tianhao; Yu, Jianan; Xiao, Guowen; Han, Yanjing; Jin, Long
• Is Part Of: Cancer biology & therapy. Volume 20:Issue 2(2019)
• Page Start: 212
• Page End: 218
• Publication Date: 2019-02-01
• Subjects: Iodine-125 seed implantation -- brachytherapy -- arterial chemoembolization -- metastatic tumor of bone -- bone neoplasms -- pain relief -- retrospective study; 616.99406
• DOI: 10.1080/15384047.2018.1523847
• Languages: English
• ISSNs: 1538-4047

Abstract

ABSTRACT: Bone metastases are the most common sites for malignant tumors. Patients who failed to respond to initial first-line treatment with bisphosphonates usually suffer from extreme pain. The aim of this study was to observe the efficacy of arterial chemoembolization combined with Iodine-125 seed implantation in the treatment of bone metastatic cancer pain. All 14 patients with metastatic bone tumor wo failed first-line treatment underwent arterial chemoembolization the day before the implantation of the particles. A computer stereoscopic TPS was used to design the treatment plans, the number and dose of particles required for implantation. Pain relief was evaluated using several parameters such as Visual Analog Scale (VAS) and Verbal Rating Scales (VRS). Pain intensity was measured pre-operation and 1-week, 1-month, 3-month after the treatment. Meanwhile, we also assessed tumor size using computer tomography (CT). Pain palliation was observed in 35.7% (5/14), 57.1% (8/14), and 78.6% (11/14) of all patients at 1-week, 1-month and 3-month post treatment. Likewise, our analysis showed that the combination therapy resulted in a significant decrease of VAS score (6.71 ± 0.49 before treatment vs 3.36 ± 0.40 at 3 month post treatment) and overall responding rate of 92.0% using VRS pain assessment. Consistently, tumor size was reduced from 42.16 ± 10.32 before treatment to 29.11 ± 8.73 at 3 months post treatment. No serious complications were detected. Our study demonstrate that the combination of arterial chemoembolization and 125 I particles resulted in evident pain relief and reduction of tumor burden, suggesting that the combination treatment could be a feasible and promising therapy for bone tumor management.